Immunovant heads into its May 29 earnings event with one of the most polarised positioning setups in the biotech space — aggressive call buying on one side, stubborn short sellers and a parade of executive sales on the other.
The options market is the loudest signal this week. The put/call ratio has collapsed to 0.05, the lowest reading of the past year and nearly three standard deviations below the 20-day average of 0.16. That is an overwhelmingly call-dominated book — investors are paying up for upside exposure into a catalyst even as the stock falls. The price is down 8.2% on the week and 10.3% over the past month, closing at $26.29. Call buyers are leaning into weakness, not momentum.
Short interest tells a less accommodating story. Bears hold roughly 11.2% of the free float — up about 6.6% in shares over the past 30 days — and show no sign of retreating ahead of the print. Borrow conditions offer no squeeze pressure to force their hand: cost to borrow is a negligible 0.40% annualised, and availability is loose at over 400% of short interest, meaning the lending pool is far from exhausted. The ORTEX short score of 71.3 places short positioning in an elevated but slightly easing range — it peaked above 74 earlier in the week before ticking down modestly. Nothing in the borrow market threatens the bears.
Insider selling complicates the picture further. CEO Eric Venker sold over $8.7 million in shares across early April transactions, the largest single block being a 334,960-share sale on April 1 at $25.10. The CFO sold just over $760,000 on April 23. The CTO, COO, and chief-level officer all sold in April as well. Net insider activity over the past 90 days shows $10.4 million in net selling. These are plan-driven transactions in many cases, but the cluster of C-suite sales running into an earnings catalyst is a data point the Street will note. Roivant Sciences still owns 55.7% of shares outstanding, anchoring the register.
The analyst community is cautiously constructive but split. Guggenheim and HC Wainwright carry Buy ratings with targets of $44 and $35 respectively, while Goldman Sachs — the most recent mover, raising its target to $32 in mid-April while holding at Neutral — sits on the sidelines. JP Morgan is Overweight with a $33 target. Truist holds at $33 target with a Hold. The mean target of $40.29 implies roughly 53% upside from current levels, a gap that reflects genuine disagreement about the IMVT-1402 pipeline rather than consensus conviction. The bull case rests on the 81% responder rate in previously antithyroid-drug-resistant patients and durable off-treatment TRAb suppression. The bear case points to persistently elevated TRAb levels driving relapse risk and uncertain market uptake. Valuation multiples are largely uninformative for a pre-profitability biotech — the price-to-book of 6.25x has compressed about 0.5 turns over 30 days as the stock has drifted lower.
Peer context adds texture. Closest correlated name ROIV — Immunovant's majority owner — fell 4.0% on the week, broadly tracking IMVT's own decline. PRME dropped 18.2% and TSHA fell 24.3%, suggesting the mid-cap biotech space broadly had a difficult week rather than IMVT facing idiosyncratic selling pressure. The prior earnings print in February produced a 14.3% one-day gain, which partially explains why call buyers are reaching for upside — the stock has a demonstrated history of moving sharply on results.
The May 29 event is therefore the lens through which every data point this week should be read: call buyers pricing in a repeat of February's upside surprise, short sellers insisting the clinical durability questions haven't been answered, and management teams who have been selling into any strength all month.
See the live data behind this article on ORTEX.
Open IMVT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
